Target Name: RETNLB
NCBI ID: G84666
Review Report on RETNLB Target / Biomarker Content of Review Report on RETNLB Target / Biomarker
RETNLB
Other Name(s): Cysteine-rich secreted protein A12-alpha-like 1 | XCP2 | Colon and small intestine-specific cysteine-rich protein found in inflammatory zone 1 | cysteine-rich secreted protein FIZZ2 | colon carcinoma-related gene protein | Colon carcinoma-related gene protein | FIZZ1 | resistin like beta | RELM-beta | C/EBP-epsilon regulated myeloid-specific secreted cysteine-rich protein precursor 2 | Resistin-like beta | Cysteine-rich secreted protein FIZZ2 | colon and small intestine-specific cysteine-rich protein | CCRG | found in inflammatory zone 1 | cysteine-rich secreted protein A12-alpha-like 1 | Colon and small intestine-specific cysteine-rich protein | RETNB_HUMAN | Resistin like beta | cysteine-rich secreted A12-alpha-like protein 1 | Csteine-rich secreted A12-alpha-like protein 1 | RELMb | RELMbeta | Colon and small intestine-specific cysteine-rich protein precursor | FIZZ2 | HXCP2

Unlocking the Potential of Cysteine-rich Secreted Protein A12-Alpha-Like 1 (RETNLB) as a Drug Target or Biomarker

Cysteine-rich secreted protein A12-alpha-like 1 (RETNLB) is a protein that has garnered significant interest due to its unique structure and function. RETNLB is a 12-kDa protein that is expressed in various tissues, including brain, heart, and pancreas, and is characterized by its cysteine-rich region. This unique feature has led to the speculation that RETNLB may serve as a drug target or biomarker. In this article, we will explore the potential of RETNLB as a drug target and biomarker.

Drug Target Potential

The cysteine-rich region of RETNLB has been identified as a potential drug target. The unique structure of RETNLB has been shown to interact with various molecules, including small molecules, peptides, and even proteins. This interactivity suggests that RETNLB may serve as a drug target for various diseases.

One of the potential benefits of targeting RETNLB is its potential to modulate inflammation. RETNLB has been shown to play a role in the regulation of inflammation and has been linked to various inflammatory diseases, including autoimmune diseases and chronic obstructive pulmonary disease (COPD). By targeting RETNLB, researchers may be able to develop new treatments for these diseases.

Another potential drug target for RETNLB is its role in the regulation of cell survival. RETNLB has been shown to be involved in the regulation of cell survival and has been linked to various diseases, including cancer. By targeting RETNLB, researchers may be able to develop new treatments for cancer.

Biomarker Potential

In addition to its potential as a drug target, RETNLB has also been suggested as a potential biomarker for various diseases. The cysteine-rich structure of RETNLB makes it a unique protein that can be used as a biomarker for various diseases.

One of the potential benefits of using RETNLB as a biomarker is its ability to cross-react with different proteins. This cross-reactivity has been shown to be a significant advantage, as it allows for the development of reliable biomarkers that can be used across different diseases.

RETNLB has been shown to be involved in the regulation of various proteins, including transcription factors, cytoskeletal proteins, and enzymes involved in energy metabolism. This involvement suggests that RETNLB may be a useful biomarker for diseases that are characterized by the disruption of these proteins.

Conclusion

RETNLB is a protein that has garnered significant interest due to its unique structure and function. The cysteine-rich region of RETNLB has been identified as a potential drug target and has been shown to interact with various molecules, including small molecules, peptides, and even proteins. In addition, RETNLB has also been suggested as a potential biomarker for various diseases due to its ability to cross-react with different proteins.

Further research is needed to fully understand the potential of RETNLB as a drug target and biomarker. By targeting RETNLB, researchers may be able to develop new treatments for various diseases.

Protein Name: Resistin Like Beta

Functions: Probable hormone

The "RETNLB Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about RETNLB comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

RETREG1 | RETREG2 | RETREG3 | RETSAT | REV1 | REV3L | Reverse transcriptase (Telomerase) | REX1BD | REXO1 | REXO1L1P | REXO1L2P | REXO1L6P | REXO1L8P | REXO2 | REXO4 | REXO5 | RFC1 | RFC2 | RFC3 | RFC4 | RFC5 | RFESD | RFESDP1 | RFFL | RFK | RFLNA | RFLNB | RFNG | RFPL1 | RFPL1S | RFPL2 | RFPL3 | RFPL3S | RFPL4A | RFPL4AL1 | RFPL4B | RFT1 | RFTN1 | RFTN2 | RFWD3 | RFX complex | RFX1 | RFX2 | RFX3 | RFX3-DT | RFX4 | RFX5 | RFX5-AS1 | RFX6 | RFX7 | RFX8 | RFXANK | RFXAP | RGCC | RGL1 | RGL2 | RGL3 | RGL4 | RGMA | RGMB | RGMB-AS1 | RGN | RGP1 | RGPD1 | RGPD2 | RGPD3 | RGPD4 | RGPD4-AS1 | RGPD5 | RGPD6 | RGPD8 | RGR | RGS1 | RGS10 | RGS11 | RGS12 | RGS13 | RGS14 | RGS16 | RGS17 | RGS18 | RGS19 | RGS2 | RGS20 | RGS21 | RGS22 | RGS3 | RGS4 | RGS5 | RGS6 | RGS7 | RGS7BP | RGS8 | RGS9 | RGS9BP | RGSL1 | RHAG | RHBDD1 | RHBDD2 | RHBDD3